While the company’s FDA approval news will accelerate its timeline for clinical trials and commercialization, Nasseo is excited to attend two prominent investor and partnership conferences later this month. Dr. Smith will present the company’s work at the Rocky Mountain Life Sciences Investor & Partnership Conference taking place September 18-19 at The Ritz-Carlton in Denver, while Kayvon Pourmirzaie, Co-Founder and COO, will represent Nasseo at the NCET2 Global 1000 Corporate Venturing Conference on September 17-18 at the Marriott San Mateo. Nasseo is seeking to close on a Series A investment/corporate partnership round by the Fall 2013.
Pourmirzaie says, “Our success so far has been based not only upon our novel technology, but also the enthusiastic support of the scientific and business communities. We will continue to evaluate new strategic partnerships that support our efforts to conduct clinically relevant studies and bring Nasseo’s highly differentiated TiArray™ Dental Implant System to market.
For more information about Nasseo’s surface modification technology, the TiArray™ Dental Implant System, investment opportunities, or to request meetings at the events listed above, please contact Kayvon Pourmirzaie at kayvon(at)nasseo(dot)com.
About the Dental Implant Market
In the United States, over 70% of adults have lost at least one permanent tooth, while 25% of American adults over 65 have lost all of their teeth. This demand amounts to a fast growing $1B+ US market. However, existing implants on the market experience high failure rates and peri-implantitis issues depending upon the tooth’s location and other factors and are not recommended for a num
Copyright©2012 Vocus, Inc.
All rights reserved